Category: Epidarex Portfolio News
Please see the full list of nominees and additional information regarding the awards here.
Motherwell, Scotland, 27th September 2018 – Clyde Biosciences, the leader in cardiac cell function assessment, announced today that its proprietary CellOPTIQ® High Content Assay (HCA) outperformed other assay types in the global CiPA myocyte study designed to develop more accurate and comprehensive in vitro cardiac…
Dr Keeney joins NodThera with over 20 years of pharmaceutical industry experience, including most recently at Sanofi and prior to that at Johnson & Johnson Cambridge, UK and Boston, MA, 24 September 2018. NodThera, a biotechnology company focused on the discovery and development of next…
CRESTWOOD, Ky., and WALTHAM Mass. – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced its Phase 3 clinical program for APL-2 in…
PHAROAH Trial Results to-Date Show APL-2 Monotherapy Eliminated Transfusion Dependency and Improved Markers of Anemia in PNH Patients on Soliris™ CRESTWOOD, Ky., and WALTHAM Mass. – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through…
London, 22 August 2018 – IGEM Therapeutics (IGEM), an immuno-oncology company developing novel immunoglobulin E (IgE) antibodies to treat cancer, today announced that it has been shortlisted as a finalist in the 2018 OBN Awards in the “Best Start-up Biotech Company” category. The “Best Start-up…
CRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track…
CRESTWOOD, Ky. and WALTHAM, Mass. — Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced that it has commenced its PEGASUS Phase 3 trial assessing the safety and…